{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:01:37Z","timestamp":1792612897296,"version":"4.5.0"},"reference-count":132,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["T32 HL07439"],"award-info":[{"award-number":["T32 HL07439"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001422","name":"American Society of Hematology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001422","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.jtct.2023.10.013","type":"journal-article","created":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T00:43:35Z","timestamp":1697849015000},"page":"171-186","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Progress and Pitfalls of Chimeric Antigen Receptor T Cell Immunotherapy against T Cell Malignancies"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9903-5021","authenticated-orcid":false,"given":"Mathew G.","family":"Angelos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruchi P.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Ruella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3280-5271","authenticated-orcid":false,"given":"Stefan K.","family":"Barta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2023.10.013_bib0001","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2023.10.013_bib0002","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2023.10.013_bib0003","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2023.10.013_bib0004","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2023.10.013_bib0005","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2023.10.013_bib0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jtct.2023.10.013_bib0007","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1007\/s11899-018-0480-8","article-title":"Novel immunotherapies for T cell lymphoma and leukemia","volume":"13","author":"Ghione","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.jtct.2023.10.013_bib0008","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","year":"2017"},{"key":"10.1016\/j.jtct.2023.10.013_bib0009","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41408-020-0337-y","article-title":"B-cell maturation antigen expression across hematologic cancers: a systematic literature review","volume":"10","author":"Dogan","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jtct.2023.10.013_bib0010","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.humpath.2012.02.004","article-title":"Advances in the molecular pathobiology of B-lymphoblastic leukemia","volume":"43","author":"Zhou","year":"2012","journal-title":"Hum Pathol"},{"key":"10.1016\/j.jtct.2023.10.013_bib0011","doi-asserted-by":"crossref","first-page":"6298","DOI":"10.1158\/1078-0432.CCR-21-1559","article-title":"Overcoming intrinsic resistance of cancer cells to CAR T-cell killing","volume":"27","author":"Lemoine","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtct.2023.10.013_bib0012","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1084\/jem.181.5.1653","article-title":"Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes","volume":"181","author":"Brocker","year":"1995","journal-title":"J Exp Med"},{"key":"10.1016\/j.jtct.2023.10.013_bib0013","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1182\/blood-2007-12-128843","article-title":"Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells","volume":"112","author":"Till","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.10.013_bib0014","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jtct.2023.10.013_bib0015","doi-asserted-by":"crossref","first-page":"16014","DOI":"10.1038\/mto.2016.14","article-title":"CAR models: next-generation CAR modifications for enhanced T-cell function","volume":"3","author":"Abate-Daga","year":"2016","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.jtct.2023.10.013_bib0016","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000496870","article-title":"Chimeric antigen receptor T cells: a race to revolutionize cancer therapy","volume":"46","author":"Subklewe","year":"2019","journal-title":"Transfus Med Hemother"},{"key":"10.1016\/j.jtct.2023.10.013_bib0017","doi-asserted-by":"crossref","first-page":"e1049","DOI":"10.1002\/cti2.1049","article-title":"Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations","volume":"8","author":"Weinkove","year":"2019","journal-title":"Clin Transl Immunol"},{"key":"10.1016\/j.jtct.2023.10.013_bib0018","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.3390\/biom12091303","article-title":"Co-stimulatory receptor signaling in CAR-T cells","volume":"12","author":"Honikel","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.jtct.2023.10.013_bib0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2022.1034707","article-title":"Next generations of CAR-T cells: new therapeutic opportunities in hematology?","volume":"13","author":"Tomasik","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtct.2023.10.013_bib0020","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41416-018-0325-1","article-title":"Teaching an old dog new tricks: next-generation CAR T cells","volume":"120","author":"Tokarew","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtct.2023.10.013_bib0021","doi-asserted-by":"crossref","unstructured":"Korell F, Laier S, Sauer S, et al. Current challenges in providing good leukapheresis products for manufacturing of CAR-T cells for patients with relapsed\/refractory NHL or ALL. Cells. 2020;9:1225.","DOI":"10.3390\/cells9051225"},{"key":"10.1016\/j.jtct.2023.10.013_bib0022","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/jca.21964","article-title":"Lack of defined apheresis collection criteria in publicly available CAR-T cell clinical trial descriptions: comprehensive review of over 600 studies","volume":"37","author":"Thibodeaux","year":"2022","journal-title":"J Clin Apher"},{"key":"10.1016\/j.jtct.2023.10.013_bib0023","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1111\/trf.17030","article-title":"Apheresis for chimeric antigen receptor T-cell production in adult lymphoma patients","volume":"62","author":"Harrer","year":"2022","journal-title":"Transfusion"},{"key":"10.1016\/j.jtct.2023.10.013_bib0024","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/trf.14003","article-title":"Autologous lymphapheresis for the production of chimeric antigen receptor T cells","volume":"57","author":"Allen","year":"2017","journal-title":"Transfusion"},{"issue":"15\\_suppl","key":"10.1016\/j.jtct.2023.10.013_bib0025","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1200\/JCO.2018.36.15_suppl.3003","article-title":"Durability of response in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B-cell lymphoma","volume":"36","author":"Locke","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.10.013_bib0026","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1158\/2159-8290.CD-18-1314","article-title":"Na\u00efve T-cell deficits at diagnosis and after chemotherapy impair cell therapy potential in pediatric cancers","volume":"9","author":"Das","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtct.2023.10.013_bib0027","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1016\/j.bbmt.2019.08.015","article-title":"Use of chimeric antigen receptor T cell therapy in clinical practice for relapsed\/refractory aggressive B cell non-Hodgkin lymphoma: an expert panel opinion from the American Society for Transplantation and Cellular Therapy","volume":"25","author":"Jain","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.10.013_bib0028","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1038\/s41409-019-0451-2","article-title":"Clinical utilization of chimeric antigen receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL): an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplant","volume":"54","author":"Kansagra","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.10.013_bib0029","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1182\/blood.V106.11.2961.2961","article-title":"Population pharmacokinetics of alemtuzumab in patients with hematologic malignancies","volume":"106","author":"Bonate","year":"2005","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2023.10.013_bib0030","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1182\/blood-2021-152692","article-title":"Phase 1\/1b safety study of Prgn-3006 Ultracar-T in patients with relapsed or refractory CD33-positive acute myeloid leukemia and higher risk myelodysplastic syndromes","volume":"138","author":"Sallman","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2023.10.013_bib0031","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1182\/blood-2021-148703","article-title":"Donor-derived CAR T cells engineered with Sleeping Beauty in pediatric and adult patients with acute lymphoblastic leukemia relapsed post-HSCT","volume":"138","author":"Magnani","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.10.013_bib0032","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1089\/hum.2017.207","article-title":"Preclinical efficacy and safety of CD19CAR cytokine-induced killer cells transfected with Sleeping Beauty transposon for the treatment of acute lymphoblastic leukemia","volume":"29","author":"Magnani","year":"2018","journal-title":"Hum Gene Ther"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2023.10.013_bib0033","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1182\/blood-2021-150469","article-title":"A phase I study of CD19 chimeric antigen receptor T cells generated by the PiggyBac Transposon vector for acute lymphoblastic leukemia","volume":"138","author":"Nishio","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.10.013_bib0034","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1007\/s00432-021-03613-7","article-title":"Phase I clinical trial of EGFR-specific CAR-T cells generated by the piggyBac transposon system in advanced relapsed\/refractory non-small cell lung cancer patients","volume":"147","author":"Zhang","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.jtct.2023.10.013_bib0035","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.abm0594","article-title":"CAR T cells produced in vivo to treat cardiac injury","volume":"375","author":"Rurik","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.jtct.2023.10.013_bib0036","first-page":"5263","article-title":"Chimeric antigen receptor T cells derived from CD7 nanobody exhibit robust antitumor potential against CD7-positive malignancies","volume":"11","author":"Chen","year":"2021","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.jtct.2023.10.013_bib0037","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1182\/bloodadvances.2017009928","article-title":"Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies","volume":"1","author":"Png","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2023.10.013_bib0038","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.omto.2022.02.013","article-title":"Feasibility study of a novel preparation strategy for anti-CD7 CAR-T cells with a recombinant anti-CD7 blocking antibody","volume":"24","author":"Ye","year":"2022","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.jtct.2023.10.013_bib0039","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jgg.2019.06.007","article-title":"Blocking CD38-driven fratricide among T cells enables effective antitumor activity by CD38-specific chimeric antigen receptor T cells","volume":"46","author":"Gao","year":"2019","journal-title":"J Genet Genomics"},{"key":"10.1016\/j.jtct.2023.10.013_bib0040","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0090-1229(88)90074-8","article-title":"Mechanisms of human CD5 modulation and capping induced by murine monoclonal antibody T101","volume":"47","author":"Shawler","year":"1988","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1016\/j.jtct.2023.10.013_bib0041","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s12015-019-09937-9","article-title":"Characterization of an anti-CD5-directed CAR T-cell against T-cell malignancies","volume":"16","author":"Wada","year":"2020","journal-title":"Stem Cell Rev Reports"},{"key":"10.1016\/j.jtct.2023.10.013_bib0042","doi-asserted-by":"crossref","first-page":"5612","DOI":"10.4049\/jimmunol.168.11.5612","article-title":"AP2 adaptor complex-dependent internalization of CD5: differential regulation in T and B cells","volume":"168","author":"Lu","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.jtct.2023.10.013_bib0043","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1182\/blood-2015-02-629527","article-title":"A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies","volume":"126","author":"Mamonkin","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.10.013_bib0044","unstructured":"Stadtmauer EA, Fraietta JA, Davis MM, et al. CRISPR-engineered T cells in patients with refractory cancer. Science. 2020;367:eaba7365."},{"key":"10.1016\/j.jtct.2023.10.013_bib0045","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2017-01-761320","article-title":"CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies","volume":"130","author":"Gomes-Silva","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.10.013_bib0046","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40364-022-00352-w","article-title":"Haploidentical CD7 CAR T-cells induced remission in a patient with TP53 mutated relapsed and refractory early T-cell precursor lymphoblastic leukemia\/lymphoma","volume":"10","author":"Dai","year":"2022","journal-title":"Biomark Res"},{"issue":"15_suppl","key":"10.1016\/j.jtct.2023.10.013_bib0047","article-title":"First-in-human clinical trial of the autologous CD7-CART for relapsed\/refractory acute lymphoblastic leukemia\/lymphoma","volume":"38","author":"Zhang","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.10.013_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2022.03.041","article-title":"Enhanced safety and efficacy of protease-regulated CAR-T cell receptors","volume":"185","author":"Labanieh","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.jtct.2023.10.013_bib0049","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1158\/2326-6066.CIR-17-0126","article-title":"Reversible transgene expression reduces fratricide and permits 4-1BB costimulation of CAR T cells directed to T-cell malignancies","volume":"6","author":"Mamonkin","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jtct.2023.10.013_bib0050","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1158\/2326-6066.CIR-16-0043","article-title":"A Tet-On inducible system for controlling CD19-chimeric antigen receptor expression upon drug administration","volume":"4","author":"Sakemura","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jtct.2023.10.013_bib0051","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-021-01418-9","article-title":"Tunable control of CAR T cell activity through tetracycline mediated disruption of protein\u2013protein interaction","volume":"11","author":"Hotblack","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtct.2023.10.013_bib0052","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1182\/blood.2021015020","article-title":"Engineering naturally occurring CD7\u2212 T cells for the immunotherapy of hematological malignancies","volume":"140","author":"Freiwan","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.10.013_bib0053","doi-asserted-by":"crossref","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2023.10.013_bib0054","doi-asserted-by":"crossref","first-page":"10402","DOI":"10.1182\/blood-2022-167804","article-title":"High metabolic tumor volume is associated with higher toxicity and decreased efficacy of BCMA CAR-T cell therapy in multiple myeloma","volume":"140","author":"Villanueva","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.10.013_bib0055","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.omtm.2021.10.006","article-title":"Peripheral leukemia burden at time of apheresis negatively affects the clinical efficacy of CART19 in refractory or relapsed B-ALL","volume":"23","author":"Deng","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jtct.2023.10.013_bib0056","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/nrclinonc.2013.100","article-title":"Minimal residual disease in acute myeloid leukaemia","volume":"10","author":"Hourigan","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jtct.2023.10.013_bib0057","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/nm.4444","article-title":"Targeting the T cell receptor \u03b2-chain constant region for immunotherapy of T cell malignancies","volume":"23:","author":"Maciocia","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.jtct.2023.10.013_bib0058","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1182\/blood-2012-01-405365","article-title":"A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR","volume":"119","author":"Torikai","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.10.013_bib0059","doi-asserted-by":"crossref","first-page":"17002","DOI":"10.18632\/oncotarget.15218","article-title":"A versatile system for rapid multiplex genome-edited CAR T cell generation","volume":"8","author":"Ren","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jtct.2023.10.013_bib0060","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1158\/1078-0432.CCR-16-1300","article-title":"Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition","volume":"23","author":"Ren","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtct.2023.10.013_bib0061","doi-asserted-by":"crossref","first-page":"eabq3010","DOI":"10.1126\/scitranslmed.abq3010","article-title":"Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia","volume":"14","author":"Ottaviano","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jtct.2023.10.013_bib0062","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/nbt.3860","article-title":"HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells","volume":"35","author":"Gornalusse","year":"2017","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jtct.2023.10.013_bib0063","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/bs.ai.2015.04.001","article-title":"HLA-G: An immune checkpoint molecule","volume":"127","author":"Carosella","year":"2015","journal-title":"Adv Immunol"},{"key":"10.1016\/j.jtct.2023.10.013_bib0064","doi-asserted-by":"crossref","unstructured":"Anna F, Bole-Richard E, LeMaoult J, et al. First immunotherapeutic CAR-T cells against the immune checkpoint protein HLA-G. J Immunother Cancer. 2021;9:e001998.","DOI":"10.1136\/jitc-2020-001998"},{"issue":"13_suppl","key":"10.1016\/j.jtct.2023.10.013_bib0065","article-title":"Abstract LB144: Overexpression of CD47 protects hypoimmune CAR T cells from innate immune cell killing","volume":"81","author":"Hu","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtct.2023.10.013_bib0066","doi-asserted-by":"crossref","first-page":"5868","DOI":"10.1182\/bloodadvances.2020002547","article-title":"Next-generation cell therapies: the emerging role of CAR-NK cells","volume":"4","author":"Basar","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2023.10.013_bib0067","doi-asserted-by":"crossref","unstructured":"Pfefferle A, Huntington ND. You have got a fast CAR: chimeric antigen receptor NK cells in cancer therapy. Cancers (Basel). 2020;12:706.","DOI":"10.3390\/cancers12030706"},{"key":"10.1016\/j.jtct.2023.10.013_bib0068","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/bloodadvances.2021006112","article-title":"Impaired immune response to COVID-19 vaccination in patients with B-cell malignancies after CD19 CAR T-cell therapy","volume":"6","author":"Dahiya","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2023.10.013_bib0069","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.ymthe.2017.01.011","article-title":"Inducible caspase-9 selectively modulates the toxicities of CD19-specific chimeric antigen receptor-modified T cells","volume":"25","author":"Diaconu","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtct.2023.10.013_bib0070","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","article-title":"Inducible apoptosis as a safety switch for adoptive cell therapy","volume":"365","author":"Di Stasi","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2023.10.013_bib0071","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/hematology.2021000225","article-title":"Relapsed ALL: CAR T vs transplant vs novel therapies","volume":"2021","author":"Frey","year":"2021","journal-title":"Hematology"},{"key":"10.1016\/j.jtct.2023.10.013_bib0072","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/ajh.25582","article-title":"Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed\/refractory B-cell acute lymphoblastic leukemia: an open-label pragmatic clinical trial","volume":"94","author":"Jiang","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtct.2023.10.013_bib0073","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.stem.2011.01.013","article-title":"LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress","volume":"8","author":"Nguyen","year":"2011","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.jtct.2023.10.013_bib0074","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2023.10.013_bib0075","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1200\/JCO.20.02262","article-title":"Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL","volume":"39","author":"Shah","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.10.013_bib0076","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jtct.2023.10.013_bib0077","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.19.01892","article-title":"Optimizing chimeric antigen receptor T-cell therapy for adults with acute lymphoblastic leukemia","volume":"38","author":"Frey","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.10.013_bib0078","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.149819","article-title":"CD7-deleted hematopoietic stem cells can restore immunity after CAR T cell therapy","volume":"6","author":"Kim","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.jtct.2023.10.013_bib0079","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1038\/s41375-018-0065-5","article-title":"An \u201coff-the-shelf\u201d fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies","volume":"32","author":"Cooper","year":"2018","journal-title":"Leukemia"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2023.10.013_bib0080","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1182\/blood-2020-136860","article-title":"CRISPR-Cas9 knockout of CD5 enhances the anti-tumor activity of chimeric antigen receptor T cells","volume":"136","author":"Chun","year":"2020","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2023.10.013_bib0081","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1182\/blood-2022-166605","article-title":"Clinical development of Senza5TM CART5: a novel dual population CD5 CRISPR-Cas9 knocked out anti-CD5 chimeric antigen receptor T cell product for relapsed and refractory CD5+ nodal T-cell lymphomas","volume":"140","author":"Patel","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.10.013_bib0082","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001150","article-title":"Point mutation in CD19 facilitates immune escape of B cell lymphoma from CAR-T cell therapy","volume":"8","author":"Zhang","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jtct.2023.10.013_bib0083","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-21168-6","article-title":"Single-cell profiling identifies pre-existing CD19-negative subclones in a B-ALL patient with CD19-negative relapse after CAR-T therapy","volume":"12","author":"Rabilloud","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtct.2023.10.013_bib0084","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1182\/blood.2021010930","article-title":"CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel","volume":"138","author":"Plaks","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.10.013_bib0085","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","article-title":"Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell","volume":"24","author":"Ruella","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.jtct.2023.10.013_bib0086","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jtct.2023.10.013_bib0087","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","article-title":"Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy","volume":"127","author":"Gardner","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.10.013_bib0088","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1016\/j.ymthe.2021.07.001","article-title":"The rational development of CD5-targeting biepitopic CARs with fully human heavy-chain-only antigen recognition domains","volume":"29","author":"Dai","year":"2021","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtct.2023.10.013_bib0089","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1182\/blood.V78.5.1173.1173","article-title":"Phase I trial of H65-RTA immunoconjugate in patients with cutaneous T-cell lymphoma","volume":"78","author":"LeMaistre","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.10.013_bib0090","doi-asserted-by":"crossref","first-page":"S237","DOI":"10.1016\/j.bbmt.2019.12.482","article-title":"CD5 CAR T-cells for treatment of patients with relapsed\/refractory CD5 expressing T-cell lymphoma demonstrates safety and anti-tumor activity","volume":"26","author":"Hill","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"suppl_1","key":"10.1016\/j.jtct.2023.10.013_bib0091","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1182\/blood-2019-129559","article-title":"Safety and anti-tumor activity of CD5 CAR T-cells in patients with relapsed\/refractory T-cell malignancies","volume":"134","author":"Hill","year":"2019","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.jtct.2023.10.013_bib0092","doi-asserted-by":"crossref","first-page":"7002","DOI":"10.1200\/JCO.2023.41.16_suppl.7002","article-title":"Enhanced anti-tumor activity of CD5 CAR T cells manufactured with tyrosine kinase inhibitors in patients with relapsed\/refractory T-ALL","volume":"41","author":"Hill","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.10.013_bib0093","first-page":"331","article-title":"Structure and function of the CD7 molecule","volume":"19","author":"Sempowski","year":"1999","journal-title":"Crit Rev Immunol"},{"key":"10.1016\/j.jtct.2023.10.013_bib0094","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1385\/IR:24:1:31","article-title":"T cell signal transduction and the role of CD7 in costimulation","volume":"24","author":"Stillwell","year":"2001","journal-title":"Immunol Res"},{"key":"10.1016\/j.jtct.2023.10.013_bib0095","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13045-019-0801-y","article-title":"Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions","volume":"12","author":"Fleischer","year":"2019","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jtct.2023.10.013_bib0096","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1200\/JCO.21.00389","article-title":"Donor-derived CD7 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia: first-in-human, phase I trial","volume":"39","author":"Pan","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.10.013_bib0097","first-page":"321","article-title":"Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL\/LBL: first-in-human phase I clinical trial","volume":"28","author":"Lu","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.10.013_bib0098","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ymthe.2022.09.003","article-title":"Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell malignancies","volume":"31","author":"Watanabe","year":"2023","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtct.2023.10.013_bib0099","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/leu.2015.311","article-title":"Preclinical targeting of human T-cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells","volume":"30","author":"Pinz","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2023.10.013_bib0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2022.997482","article-title":"Treatment of aggressive T-cell lymphoma\/leukemia with anti-CD4 CAR T cells","volume":"13","author":"Feng","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtct.2023.10.013_bib0101","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1172\/JCI94306","article-title":"Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes","volume":"127","author":"Ramos","year":"2017","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jtct.2023.10.013_bib0102","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1200\/JCO.20.01342","article-title":"Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma","volume":"38","author":"Ramos","year":"2020","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2023.10.013_bib0103","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1182\/blood-2018-99-116741","article-title":"Anti-CD30 chimeric antigen receptor T cell therapy for CD30+ relapsed\/refractory Hodgkin lymphoma and anaplastic large cell lymphoma patients","volume":"132","author":"Wang","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.10.013_bib0104","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/0092-8674(92)90180-K","article-title":"Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease","volume":"68","author":"Durkop","year":"1992","journal-title":"Cell"},{"key":"10.1016\/j.jtct.2023.10.013_bib0105","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13046-021-02215-y","article-title":"The CD70-CD27 axis in oncology: the new kids on the block","volume":"41","author":"Flieswasser","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.jtct.2023.10.013_bib0106","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1182\/blood.2020008221","article-title":"CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity","volume":"138","author":"Sauer","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.10.013_bib0107","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/hon.2438_148","article-title":"CD70 expression in cutaneous T cell lymphoma (CTCL) patients and mechanisms of action of ARGX-110 in skin: histopathological and clinical data","volume":"35","author":"Hultberg","year":"2017","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.jtct.2023.10.013_bib0108","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003289","article-title":"CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment","volume":"10","author":"Seyfrid","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"6_suppl","key":"10.1016\/j.jtct.2023.10.013_bib0109","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1200\/JCO.2022.40.6_suppl.384","article-title":"CD70 is a promising CAR-T cell target in patients with advanced renal cell carcinoma","volume":"40","author":"Ye","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.10.013_bib0110","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/01.HS9.0000843940.96598.e2","article-title":"S262: The COBALT-LYM study of CTX130: a phase 1 dose escalation study of CD70-targeted allogeneic CRISPR-CAS9-engineered CAR T cells in patients with relapsed\/refractory (R\/R) T-cell malignancies","volume":"6","author":"Iyer","year":"2022","journal-title":"HemaSphere"},{"key":"10.1016\/j.jtct.2023.10.013_bib0111","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/s41573-020-0084-6","article-title":"Base editing: advances and therapeutic opportunities","volume":"19","author":"Porto","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jtct.2023.10.013_bib0112","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41551-019-0357-8","article-title":"Adenine base editing in an adult mouse model of tyrosinaemia","volume":"4","author":"Song","year":"2020","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.jtct.2023.10.013_bib0113","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/s41587-021-00933-4","article-title":"In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels","volume":"39","author":"Rothgangl","year":"2021","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jtct.2023.10.013_bib0114","first-page":"2","article-title":"Functionalized lipid-like nanoparticles for in vivo mRNA delivery and base editing","volume":"6","author":"Zhang","year":"2020","journal-title":"Sci Adv"},{"key":"10.1016\/j.jtct.2023.10.013_bib0115","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1038\/s41375-021-01282-6","article-title":"Base-edited CAR T cells for combinational therapy against T cell malignancies","volume":"35","author":"Georgiadis","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2023.10.013_bib0116","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1182\/blood.2022015825","article-title":"Cytosine base editing enables quadruple-edited allogeneic CART cells for T-ALL","volume":"140","author":"Diorio","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.10.013_bib0117","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa2300709","article-title":"Base-edited CAR7 T cells for relapsed T-cell acute lymphoblastic leukemia","volume":"389","author":"Chiesa","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2023.10.013_bib0118","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1182\/blood.2021013648","article-title":"Anti-CCR9 chimeric antigen receptor T cells for T cell acute lymphoblastic leukemia","volume":"140","author":"Maciocia","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2023.10.013_bib0119","doi-asserted-by":"crossref","first-page":"10316","DOI":"10.1182\/blood-2022-165971","article-title":"First in human study of AUTO4, a TRBC1-targeting CAR T-cell therapy in relapsed\/refractory TRBC1-positive peripheral T-cell lymphoma","volume":"140","author":"Cwynarski","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.10.013_bib0120","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jtct.2023.10.013_bib0121","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1158\/2326-6066.CIR-20-0675","article-title":"CD19\/CD22 dual-targeted CAR T-cell therapy for relapsed\/refractory aggressive b-cell lymphoma: a safety and efficacy study","volume":"9","author":"Wei","year":"2021","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jtct.2023.10.013_bib0122","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.ymthe.2021.08.033","article-title":"A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALL","volume":"30","author":"Zanetti","year":"2022","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtct.2023.10.013_bib0123","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41392-022-00898-z","article-title":"T cells expressing CD5\/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape","volume":"7","author":"Dai","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2023.10.013_bib0124","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1182\/blood-2022-158684","article-title":"Epitope editing in hematopoietic cells enables CD45-directed immune therapy","volume":"140","author":"Wellhausen","year":"2022","journal-title":"Blood"},{"issue":"suppl","key":"10.1016\/j.jtct.2023.10.013_bib0125","article-title":"P356: Phase 1\/2 dose-escalation study of anti-CD7 allogenic CAR-T cell in relapsed or refractory (R\/R) T-cell acute lymphoblastic leukemia\/lymphoblastic lymphoma (T-ALL\/LBL)","volume":"7","author":"Ghobadi","year":"2023","journal-title":"Hemasphere"},{"key":"10.1016\/j.jtct.2023.10.013_bib0126","doi-asserted-by":"crossref","unstructured":"Riches ML, Shea TC, Ivanova A, et al. Infusion of CD30 CAR T cells is safe and effective as consolidation following autologous hematopoietic stem cell transplant. Presented at: 2021 Transplantation & Cellular Therapy (TCT ) Meetings of ASTCT and CIBMTR. February 8-12, 2021; digital experience.","DOI":"10.1016\/S2666-6367(21)00093-2"},{"key":"10.1016\/j.jtct.2023.10.013_bib0127","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1182\/bloodadvances.2021005385","article-title":"Pretherapy metabolic tumor volume is associated with response to CD30 CAR T cells in Hodgkin lymphoma","volume":"6","author":"Voorhees","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2023.10.013_bib0128","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-153968","article-title":"CD30-Directed chimeric antigen receptor (CAR)-T cells for treatment of Hodgkin lymphoma and non-Hodgkin lymphoma in pediatric patients","author":"Hucks","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2023.10.013_bib0129","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1182\/blood-2022-160244","article-title":"CD30 CAR-modified Epstein-Barr virus-specific T cells (CD30) CAR EBVSTs) provide a safe and effective off-the-shelf therapy for patients with CD30-positive lymphoma","volume":"140","author":"Quach","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2023.10.013_bib0130","doi-asserted-by":"crossref","first-page":"12731","DOI":"10.1182\/blood-2022-157149","article-title":"Transient responses and significant toxicities due to cytopenias and rashes with anti-CD30 CAR T cells for CD30-expressing lymphomas: results of a phase I clinical trial","volume":"140","author":"Brudno","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.10.013_bib0131","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-148102","article-title":"CD30-directed CAR-T cells co-expressing CCR4 in relapsed\/refractory Hodgkin lymphoma and CD30+ cutaneous T cell lymphoma","author":"Grover","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2023.10.013_bib0132","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1182\/blood-2021-146236","article-title":"Phase 1 study of CD37-directed CAR T cells in patients with relapsed or refractory CD37+ hematologic malignancies","volume":"138","author":"Frigault","year":"2021","journal-title":"Blood"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636723016160?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636723016160?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:12:41Z","timestamp":1763003561000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636723016160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":132,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S2666636723016160"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2023.10.013","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Progress and Pitfalls of Chimeric Antigen Receptor T Cell Immunotherapy against T Cell Malignancies","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2023.10.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}